Cardiovascular diseases (CVDs) are disorders of the heart and blood vessels and the leading cause of death globally. Many CVDs, such as ischemic heart disease, cause cardiac injury by loss of cardiomyocytes. The surviving cardiomyocytes have limited proliferative capacity and dead cardiomyocytes are replaced by non-contractile fibrous tissue. Reduction of cardiac muscle eventually leads to heart failure where the heart is unable to circulate enough blood to meet the body’s metabolic requirements. Current therapy for cardiovascular diseases can delay the progression but cannot cure the heart failure. Recent evidence has suggested that stem cell therapy can regenerate the injured heart; however, there needs to be substantial work left before this novel therapy becomes standard practice.
So far, many preclinical studies for cardiovascular regeneration have been performed in ischemic injury procedures in multiple animal models; however, it is largely unknown that regenerative medicine provides beneficial effects in other cardiovascular diseases, including genetic and non-genetic etiologies, indicating the need to clarify the target diseases. In addition, treatment procedure, including, cell preparation, cell number, delivery approach, treatment timing, and immunosuppression protocol, needs to be standardized. These issues can be verified by preclinical studies using appropriate animal models.
This research topic focuses on animal studies, ranging from rodent to large animal models, for cardiovascular regeneration. We expect both Original Research and Review Articles.
Potential topics include but not limited to the following:
1) Translational research to obtain proof-of-concept for novel therapy
2) Large animal study for cardiovascular regeneration.
3) Allogeneic or autologous transplantation study to regulate post-transplant immunity.
4) Animal study to refine clinical protocols.
5) Animal study to elucidate cardiovascular regenerative mechanisms.
6) Genetically established disease models for researches of
cardiovascular regenerative medicine.
Cardiovascular diseases (CVDs) are disorders of the heart and blood vessels and the leading cause of death globally. Many CVDs, such as ischemic heart disease, cause cardiac injury by loss of cardiomyocytes. The surviving cardiomyocytes have limited proliferative capacity and dead cardiomyocytes are replaced by non-contractile fibrous tissue. Reduction of cardiac muscle eventually leads to heart failure where the heart is unable to circulate enough blood to meet the body’s metabolic requirements. Current therapy for cardiovascular diseases can delay the progression but cannot cure the heart failure. Recent evidence has suggested that stem cell therapy can regenerate the injured heart; however, there needs to be substantial work left before this novel therapy becomes standard practice.
So far, many preclinical studies for cardiovascular regeneration have been performed in ischemic injury procedures in multiple animal models; however, it is largely unknown that regenerative medicine provides beneficial effects in other cardiovascular diseases, including genetic and non-genetic etiologies, indicating the need to clarify the target diseases. In addition, treatment procedure, including, cell preparation, cell number, delivery approach, treatment timing, and immunosuppression protocol, needs to be standardized. These issues can be verified by preclinical studies using appropriate animal models.
This research topic focuses on animal studies, ranging from rodent to large animal models, for cardiovascular regeneration. We expect both Original Research and Review Articles.
Potential topics include but not limited to the following:
1) Translational research to obtain proof-of-concept for novel therapy
2) Large animal study for cardiovascular regeneration.
3) Allogeneic or autologous transplantation study to regulate post-transplant immunity.
4) Animal study to refine clinical protocols.
5) Animal study to elucidate cardiovascular regenerative mechanisms.
6) Genetically established disease models for researches of
cardiovascular regenerative medicine.
